Application-based market taxonomy reveals that gastro-oesophageal reflux disease (GERD) accounts for 39 % of 2023 demand; patients on proton-pump inhibitors co-prescribe simethicone to break gastric foam, creating a sticky, repeat-purchase stream worth USD 96 million. The irritable bowel syndrome (IBS) segment contributes 28 % and exhibits the strongest per-capita consumption in North America, where guideline inclusion has doubled prescription share since 2018. Post-operative gas relief, largely laparoscopic and bariatric cases, represents 18 %; although episode volume is small, unit vials of concentrated simethicone suspension command 3× the OTC tablet ASP, lifting profit pools. Paediatric colic and other minor indications make up the remaining 15 %, but regulatory pressure against off-label use is tempering growth to <3 % CAGR. Collectively, these application pockets define how clinical evidence maps to revenue, anchoring any forward-looking forecast for the Simethicone Preparations market.